FM NOVEMBER 2018 ISSUE - digital edition

legal and regulatory approvals.
Besides precision dosing
apps, BaseCase Portal can also
be used for diverse purposes
such as providing education
and facilitating collaboration.
Examples include apps that
provide product information,
inform on guidelines and
treatment pathways, and track
the progress of global studies.
As BaseCase Portal is a
white label solution, it can be
tailored to reflect each clients’
brand identity, Certara informs.
BTG launches
cryoablation
system
BTG plc has announced the
global launch of the ICEfx
Cryoablation System. ICEfx,is
an updated version of the
existing Visual ICE system is
designed for interventional
radiologists who want to
offer their patients minimally
invasive treatment options.
It allows physicians to
provide safe and efficient
cryoablation procedures,
facilitating precise and
effective treatment without
the need for surgery or
repeated radiation treatments.
The advanced cryoablation
technology is currently
supporting a number of active
clinical research studies in
bone, kidney, lung, pain, and
prostate, the company said.
BTG Interventional
Oncology delivers IO ablation
solutions across multiple
physician specialties.
Stent to seal
coronary artery
tears cleared
The US FDA has cleared PK
Papyrus Covered Coronary
Stent System, a device to
treat acute coronary artery
perforations or tears in the
blood vessels of the heart.
A coronary artery
perforation can occur during
Percutaneous Coronary
Guide XT system for
visualization of DBS
Guide XT System for
visualization of deep
brain stimulation (DBS)
was launched in Europe,
said Boston Scientific
Corporation.
The Guide XT System
is built for directionality
that utilizes patientspecific
anatomy and
stimulation field modeling.
This technology provides
physicians with 3-D image
planning capability and
when used in conjunction
with the Vercise DBS
Systems, enables physicians
to personalise and optimise
DBS treatment.
DBS treats movement
disorder symptoms in
patients with Parkinson’s
disease, dystonia or essential
tremor. The procedure
stimulates a targeted
Intervention (PCI) procedures.
The PK Papyrus Stent
System is a balloonexpandable
covered coronary
stent and delivery system.
The device is advanced into
the perforated coronary
artery vessel using a balloon
catheter, similar to the
one used during the PCI
procedure. Once the PK
Papyrus stent is implanted,
it provides a physical barrier
to seal the tear in the artery
wall while still allowing
region of the brain through
implanted leads that are
powered by a device called
an implantable pulse
generator (IPG).
The Guide XT System
automatically detects
the location of the
leads, implanted by a
neurosurgeon, in the
imaging of the brain.
Following the implant, a
clinician programmes a
patient’s device and the
Guide XT System can be
used to help visualize
the stimulation field and
efficiently determine the
most appropriate settings for
each patient.
Guide XT was developed
in partnership with
Brainlab AG, a softwaredriven
medical technology
company.
blood to flow through the
device to the heart muscle.
Successful sealing of a
coronary perforation with the
PK Papyrus Covered Coronary
Stent System can be a lifesaving
procedure without the
need for open-heart surgery.
The FDA reviewed realworld
survey data from
80 patients who received
PK Papyrus stents to treat
coronary artery perforations.
PK Papyrus stents were
successfully delivered to the
perforation site in 76 of the
80 patients (95 percent), and
the device successfully sealed
the perforation in 73 patients
(91.3 percent), according to
US FDA.
Micro pump for
Parkinson’s gets
CE mark
Sensile Medical AG, a
Swiss medical technology
company, said its wearable
micro pump has received CE
certification from EU.
The micro pump is
designed to be used in
the treatment of advanced
Parkinson’s disease. The
handy-sized, discreet
pump has got easy to use
features such as automatic
filling with liquid medicine.
Technologies such as colour
display, charging unit and data
storage help enhance therapy
management.
A personally
programmable basal profile
enables treatment to be
optimized for Parkinson’s
patients and ensures that they
receive the precise dosage
they need. Likewise for the
bolus rate: A patient can
cause the device to deliver
a bolus at just one touch of
a button. Sensile’s patented
SenseCore micro rotary
piston pump in the device
ensures safe, precise drug
delivery, eliminating flow rate
calculations.
86 / FUTURE MEDICINE / NOVEMBER 2018